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Lung cancerPurpose: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers
that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary
descriptive data.
Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight
countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients
had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was pre-
scribed according to local regimens, but centres used standardised data collection forms. Pre-treatment
blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate)
months and summary descriptive statistics were generated.
Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer
patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901)
reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data
are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung).
Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA
(n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of
2-year (1-year for lung) grade 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate)
and 27% dyspnoea (lung).
Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the
radiotherapy community for validating predictive models and biomarkers.
Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding
healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life.
Not all patients are equally sensitive to radiation ‘‘damage” but it is not possible at the moment to iden-
tify those who are. REQUITE was established with the aim of trying to understand more about how we
could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary
of the data and material available.
In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and
donated blood. A large amount of data was collected in the same way. With all these data and samples
a database and biobank were created that showed it is possible to collect this kind of information in a
standardised way across countries.
In the future, our database and linked biobank will be a resource for research and validation of clinical
predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how
many people suffer with radiotherapy toxicity.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 138 (2019) 59–67 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Up to half of cancer patients undergo radiotherapy [1] and irra-
diation of surrounding healthy tissue is unavoidable. Patients vary
in sensitivity to ionising radiation with 5–10% suffering from sev-
ere long-term effects that impact on their health-related quality-
of-life [2,3] and limit the potentially curative doses prescribed to
the majority.
The ability to predict those patients likely to develop adverse
effects could potentially enable individualised treatments, which
could decrease morbidity and/or increase survival. Models includ-
ing clinical/treatment data and biomarkers have been developed to
try identifying radiosensitive patients, e.g. [4–6]. However, the
developed models and biomarkers have failed to progress to rou-
tine clinical use due to the lack of thorough independent valida-
tion. The ability to validate findings has been hampered by the
lack of cohorts available. Cohorts are often small and heteroge-
neous [7–10]. Use of different toxicity scoring systems and the lack
of standardised data collection reduces the ability to pool data [11],
which is essential for collaborative research exemplified by Radio-
genomics Consortium studies [12–19].
REQUITE (validating pREdictive models and biomarkers of
radiotherapy toxicity to reduce side effects and improve QUalITy
of lifE in cancer survivors) was established with the aim of validat-
ing models and biomarkers that predict a cancer patient’s risk of
adverse effects following radiotherapy [20]. In order to address
previous limitations in pooling data and validating models and
biomarkers, REQUITE carried out an international, multi-centre,
prospective observational study. To reflect the real-life situation
required for application of predictive models, there was nostipulation of the radiotherapy regimens to be delivered. However,
all centres collected the same data housed in a central easily acces-
sible database: demographics, previous and present co-morbidity,
treatment and dosimetric information, longitudinal standardised
radiotherapy toxicity (health professional and patient reported),
and quality-of-life. A centralised biobank was established to store
blood samples (extracted DNA, PAXgene tubes). Genome-wide
genotyping of single nucleotide polymorphisms (SNPs) was carried
out and the data added to the centralised database. A radiation-
induced lymphocyte apoptosis (RILA) assay was carried out on a
sub-set of patients.
The comprehensive centralised database and linked biobank
will be a resource for the prospective evaluation and validation
of clinical predictors and models. REQUITE will also enable a better
understanding of the scale of radiotherapy toxicity in a multi-
national setting. As REQUITE is a resource for dissemination and
exploitation to the radiotherapy community, the purpose of this
paper is to provide a comprehensive overview and summary of
the data and material available.Study design and methods
Study design and recruitment
A multi-centre, prospective observational cohort study was
designed to recruit 5300 patients with breast, lung or prostate can-
cer undergoing radiotherapy with curative intent. The study aim
was validating predictive models and biomarkers of radiotherapy
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meetings and out-patient clinics of 26 hospitals (Supplementary
Table S1) in eight countries (Belgium, France, Germany, Italy, the
Netherlands, Spain, UK, the USA). Adult breast and prostate cancer
patients were recruited prior to radiotherapy between 04/2014
and 10/2016 and lung cancer patients until 03/2017 (Supplemen-
tary Table S2 with inclusion and exclusion criteria). Conventional
and hypofractionated radiotherapy was prescribed according to
local standard-of-care regimens. The patients were followed
prospectively for a minimum of 12 (lung) or 24 (breast and pros-
tate) months, with longer follow-up encouraged where possible.
The primary study endpoints were change in breast appearance
(breast cancer patients), rectal bleeding (prostate) at 24 months
and dyspnoea/breathlessness at 12 months (lung). Toxicity evalua-
tion beyond these time points was encouraged. Primary and sec-
ondary endpoints are summarised in Supplementary Table S3. All
patients gave written informed consent. The study was approved
by local ethics committees and is registered at www.controlled-tri-
als.com ISRCTN98496463.
Data and sample collection
Patients were recruited prior to radiotherapy (baseline) and fol-
lowed as previously described (Fig. 1). The following standardisedFig. 1. Study Schema. Breast (B), prostate (P) and lung (L) cancer patients were recruited
was assessed prospectively by healthcare professionals (CTCAE v4.0, common terminolo
end of radiotherapy (B, P), 3 and 6 months (L), 12 months and 24 months. Data collected
(DICOMs: Digital Imaging and Communications in Medicine, DVHs: dose–volume histo
assessed using the European Organisation for Research and Treatment of Cancer (EORT
Multidimensional Fatigue Inventory (MFI) and the Global Physical Activity Questionnaire
24 months. BCCT.core: (Breast Cancer Conservation Treatment.cosmetic results).data were collected prospectively by case report forms (CRFs):
demographics, co-morbidity, treatment (with comprehensive
information on radiotherapy regimens and dose to organs at risk),
physics, longitudinal standardised radiotherapy toxicity (CTCAE
v4.0 healthcare professional and patient reported), quality-of-life,
and treatment outcome (including physician reported death). Both
acute (at end of radiotherapy or at 3 months) and late toxicity data
at 12 and 24 months are available for all three cancer types. Patient
reported outcome (PRO) data collected were: quality-of-life
including fatigue (EORTC QLQ C30 [21]; BR23 [22]; MFI [23] and
physical activity (GPAQ [24])). CTCAE v4.0 based questionnaires
developed to collect PRO data were adapted from those published
elsewhere for the male pelvis [25] and lung [26]. The patient ques-
tionnaires were translated into local languages by two native
speakers, merged, back translated by native English speakers, and
validated for usability in ten patients per country.
DICOM and DVH files were collected for central storage using a
standardised operating procedure (SOP). For the breast cancer
patients, breast photos were taken using a SOP before radiotherapy
and at the 24-month time point, and scored using BCCT.core soft-
ware [27] according to a SOP, with 5% of photographs re-scored for
quality assurance. A SOP was also produced for collecting blood
samples. All patients donated at least two blood samples prior toprior to radiotherapy and blood samples taken pre-radiotherapy (baseline). Toxicity
gy criteria for adverse effects) and patients (patient reported outcomes, PRO) at the
included comprehensive cancer treatment data including radiotherapy physics data
grams), comorbid and other patient-related information. Quality-of-life (QoL) was
C) QLQ C30 and the breast specific module BR23 (breast cancer patients only), the
(GPAQ). For breast cancer patients, photos of the breasts were taken at baseline and
62 REQUITE cohort characteristicsthe start of radiotherapy: an EDTA sample for SNP genotyping plus
a PAXgene (RNA) and/or a Lithium Heparin (LiH) sample. Blood
samples were dispatched according to a SOP under temperature-
controlled conditions to the CIGMR Biobank in Manchester, UK,
where extracted DNA from blood and PAXgene samples for future
RNA analysis are stored. A subset of patients from France, Germany
and the UK gave LiH blood samples for prospective radiation-
induced lymphocyte apoptosis (RILA) assays using an established
method [7] and standardization across laboratories [28]. Genotyp-
ing data were generated using the Illumina Infinium OncoArray-
500K beadchip. Following standard quality control procedures
[29], genotype data were imputed using the 1000 Genomes Project
(version 3) as a reference panel. The REQUITE CRFs, questionnaires
and SOPs are available on request via www.requite.eu.Data management and quality control
Each patient was assigned a unique study identifier, which links
sample, health and genetic data. The ID includes a check digit to
minimise errors. Data were uploaded by each recruitment site to
a secure, online centralised database system (OpenClinica
(https://openclinica.com), LimeSurvey (https://limesurvey.org)
and a bespoke ‘Manager’ application based on Drupal 7
(https://drupal.org)) with personal logins. Quality assurance and
control procedures involved site initiation visits prior to the start
of the study, monitoring visits during the study, transcribing error
checks, source data verification and plausibility checks including a
query system. Blood and DNA samples were 2D labelled. The study
is overseen by a Steering Committee that includes a Patient Advi-
sory Board.Analytical considerations and statistical analysis
It was initially estimated that 2-year toxicity data would be
available for 75% of enroled patients, i.e. 1575 of the original target
of 2100 breast or prostate cancer patients. Based on effect sizes
observed for genetic associations with radiation toxicity (e.g.
[17]), a power calculation for the genetic assay showed that 1575
breast or prostate cancer patients has 80% power to detect a rela-
tive risk (RR) of >1.56 for grade 2 toxicity (a = 5  105 for
1000 SNPs, allele frequency = 0.25, toxicity rate = 20%). For 825
patients with lung cancer the detectable RR would be 1.78. A Krus-
kal–Wallis test was used for comparisons between the three cancer
types using SAS 9.4. Graphs were generated using R 3.5.1, ggplot
3.0.0 or SAS 9.4.Results
Cohort characteristics
Within the time-period available, 4438 patients were enroled:
2069 breast (99% of the original target), 1808 prostate (86%) and
561 lung (51%) cancer patients. Comprehensive cancer treatment
data were available for 2057 breast, 1760 prostate and 530 lung
cancer patients. The baseline characteristics and treatment infor-
mation are summarised for each cancer type in Tables 1–3. Patients
were aged between 23 and 91 years. The breast cancer patients
were younger (median 58 years) at enrolment than the prostate
(70 years) and lung (69 years) cancer patients. Most patients
(>94%) identified as being of European ancestry (data not shown).
As expected, there were significantly more lung cancer patients
who were current smokers at the time of diagnosis (43%) compared
with breast (18%) and prostate (14%) patients (p < 0.001). Patients
with lung (17%) and prostate (13%) cancer were also more likely
than breast patients (6%) to have diabetes (p = 0.049).The age distribution did not vary substantially by country, but
per-centre analyses highlight some heterogeneity in patients and
treatments across centres/countries that might pose a challenge
when attempting to validate predictive models and biomarkers.
For example, cancer patients tended to have a higher BMI in Spain
and the UK than in the other countries (Supplementary Fig. S1a),
and the proportion of in situ breast tumours ranged from <10%
(Italy, Spain, UK) to 25% in the US centre. About one third of the
breast cancer patients received adjuvant or neoadjuvant
chemotherapy, with rates varying from 20% (France, UK, US) to
>40% (Italy, Spain). Half of the breast cancer patients were treated
with intensity-modulated radiotherapy (IMRT), with a lower pro-
portion in France and no IMRT in Italy and the US. Breast cancer
patients who received IMRT ranged from <20% (France, Italy, Spain,
US) to >80% (Belgium, UK). Most patients received an additional
boost (68%), with lower proportions in the US (40%) and UK
(10%). Hypofractionation rates were highest in Belgium and UK.
For the prostate cancer patients, 27% had a prostatectomy prior
to radiotherapy (Table 2). As patients with and without previous
prostatectomy differ, their characteristics are reported separately.
Post-prostatectomy patients were younger, reported fewer comor-
bidities (e.g. hypertension: p < 0.001), had a higher risk class and
received lower radiotherapy doses than those who underwent rad-
ical radiotherapy. The proportion of patients having a prostatec-
tomy prior to radiotherapy varied from 7% in the UK to 55% in
Belgium (Supplementary Fig. S1b). In terms of their treatment,
most prostate cancer patients received 74–81 Gy with 1.8–2.0 Gy
per fraction (68% of the radically irradiated patients) or 66–72 Gy
with 1.8–2.0 Gy per fraction (66% of the post-prostatectomy
patients). About one third of the radically treated patients and
10% of the post-prostatectomy patients received hypofractionation
regimens. Most patients received Rapid arc/VMAT radiotherapy,
except in Spain where 3D-conformal radiotherapy and brachyther-
apy were used (Supplementary Fig. S1c). In the US centre, about
half of patients underwent brachytherapy. The proportion receiv-
ing hormone treatment varied from 13% (Germany) to about 80%
(Belgium, UK). About 26% of the patients received hypofractiona-
tion with highest rates in Belgium, the Netherlands and UK (Sup-
plementary Fig. S1d).
For the lung cancer patients (Table 3), 9% had surgery prior to
radiotherapy with the highest proportion in Spain (19%, Supple-
mentary Fig. S1e). About half of the patients received chemother-
apy, mostly applied concurrently. Radiotherapy techniques varied
widely across countries with the highest IMRT rates in Belgium
and the US (Supplementary Fig. S1f). Most French patients were
treated with stereotactic radiotherapy. Tomotherapy was only
used at the Italian site. Moderate hypofractionation rates were
highest in Belgium, Italy, the Netherlands and UK (Supplementary
Fig. S1g).Baseline levels of toxicity and quality-of-life scores
The pre-radiotherapy baseline level of adverse effects for both
healthcare professional rated CTCAE v4.0 scoring as well as patient
reported outcomes are presented in Supplementary Figs. S2a–2d
by cancer type. They highlight that across all cancers and toxicities
healthcare professional graded scores are lower than patients’
grades, in particular for breast pain, certain genitourinary prostate
symptoms and lung toxicities. Healthcare professional rated base-
line toxicity data were available for >99.8% of the patients with
radiotherapy data: 2056 breast, 1758 prostate and 529 lung. PROs
were filled in by 2000 breast (97.2%), 1681 prostate (95.5%) and
462 lung (87.2%) cancer patients. In general, adverse effects grade
2 evaluated by a physician were low at baseline (particularly for
gastrointestinal related toxicities in prostate cancer patients) and
Table 1
Baseline characteristics of the REQUITE breast cancer patients.
Characteristics Breast cancer patients (N = 2057)
Age at enrolment Median (range), years 58 years (23–90)
BMI Mean (standard deviation), kg/m2 26.5 kg/m2 (±5.6)
Smoking status at diagnosis Current 365 (18%)
Former 514 (25%)
Never 1156 (56%)
Selected comorbidities Diabetes, antidiabetics 127 (6%)
Heart disease 143 (7%)
Delayed healing >3 weeks post-surgery 52 (3%)
Post-operative haematoma 260 (13%)
Post-operative oedema 145 (7%)
Post-operative infection 91 (4%)
Family history of breast cancer First degree relatives 410 (20%)
Tumour size (pre-radiotherapy) in situ 252 (12%)
T1-T2 1728 (84%)
T3, T4 16 (<1%)
Nodal status (pre-radiotherapy) Negative 1488 (72%)
Positive 394 (19%)
Tumour histology Infiltrating ductal 1318 (64%)
Other (including lobular, in situ, mixed) 739 (36%)
Oestrogen receptor positive 1667 (81%)
HER2 positive 1581 (10%)
Additional cancer treatment Chemotherapy 638 (31%)
Tamoxifen, aromatase inhibitors 1574 (77%)
Anti-HER2, targeted therapy 170 (8%)
Radiotherapy IMRT 1018 (49%)
Patients without boost* 662 (32%)
50–56 Gy/ 2.0 Gy*2 203 (31%)
39.9–45 Gy/2.5–3.2 Gy 452 (68%)
28.5–32.5 Gy/5.7–6.5 Gy 7 (1%)
Patients with simultaneous boost** 257 (12%)
50–52 Gy/ 2.0 Gy + 6–15.6 Gy/0.2–0.5 Gy (partly plus 2 Gy)*3 179 (70%)
40.05 Gy/2.67 Gy + 6.75–10.95 Gy/0.45–0.73 Gy 35 (14%)
28.5 Gy/5.7 Gy + 4–6 Gy/0.8–1.2 Gy 43 (17%)
Patients with sequential boost** 1138 (55%)
50 Gy/2.0 Gy + 9–20 Gy/2–3 Gy*4 641 (56%)
39.6–49.5 Gy/2.25–3.6 Gy + 10–16 Gy/2.0–3.99)*5 380 (33%)
Brachytherapy boost** 117 (10%)
50.0 Gy/2.0 Gy + 8.5–10 Gy/8.5–10 Gy 40 (34%)
39.9–42.56/2.66 Gy + 8.5–10 Gy/5–10 Gy 77 (66%)
BMI: Body mass index. IMRT: Intensity modulated radiation therapy.
*RT regimens: Total whole breast irradiation dose (WBI)/fraction dose.
**RT regimens: Total whole breast irradiation (WBI)/fraction dose + total boost dose/fraction dose.
*2Including 6 patients with WBI dose <50 Gy.
*3Including 24 patients with 4 Gy or 10 Gy from sequential boost in 2 Gy fractions; 1 patient with WBI dose <50 Gy.
*4Including 24 patients with WBI dose <50 Gy; 3 patients with boost dose <9 Gy or boost fraction dose >3 Gy.
*5Including 4 patients with boost dose <10 Gy; 2 patients with boost dose 18.6 Gy.
BMI: Body mass index. IMRT: intensity-modulated radiotherapy. WBI: Whole breast irradiation dose. Numbers might not add up due to missing data.
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ual dysfunctions among prostate cancer patients (e.g. 27% erectile
dysfunction) and dyspnoea in lung cancer patients (23%).
A total of 2000breast (97.2%), 1665prostate (94.6%) and457 lung
cancer patients (86.2%) filled in the EORTC QLQ C30 quality-of-life
baseline questionnaire (Supplementary Table S4, transformed into
a scale of 0–100). Supplementary Table S5 shows the differences in
baseline toxicities and quality-of-life data by country.Summary of data available
Supplementary Table S6 provides an overview of the REQUITE
resource and summarises the comprehensive data and samples
available at the end of the funding period (October 2018). More
than 45,000 physician and over 50,000 patient forms (including
quality-of-life, fatigue and physical activity) were collected. Breast
photos at baseline and 24-month of over 1500 breast cancer
patients were scored to assess changes in breast appearance. More
than 17,000 DVHs and 12,000 DICOMs for organs at risk were
uploaded. Imputed genotype data are available for >4200 REQUITE
patients with European ancestry (55.2 billion genotypes). About
1300 patients also have data on the radiation-induced lymphocyte
assay. A PAXgene tube was collected from >3000 patients for
future RNA analysis.As of October 2018, follow-up CTCAE v4.0 toxicity data are
available for about 1700 breast (82% of recruited patients) and
1430 prostate (79%) at 24 months and for 330 lung cancer patients
(59%) at 12 months. For breast, common toxicity rates with grade
2 at 2 years were 5–13%, for prostate below 5% for GI toxicities,
3–8% for GU toxicities and 20–31% for sexual problems. Com-
mon lung toxicity rates at one year were 4–7% and dyspnoea
rates at 27%.Discussion
REQUITE is one of the largest radiotherapy patient cohorts with
standardised longitudinal data and sample collection from multi-
ple hospitals and countries. To overcome issues of heterogeneity
encountered in previous cohorts, considerable efforts were made
to ensure standardisation of data collection, which include quality
assurance and quality control measures. It is hoped that other
studies will use the CRFs and multi-lingual CTCAE v4.0 PRO ques-
tionnaires to further improve data collection and our ability to val-
idate models and biomarkers of radiosensitivity [20]. Although
established as a resource to validate predictive models, we antici-
pate its use also in discovery science, e.g., in contributing data to
radiogenomics studies identifying common genetic variants asso-
ciated with risk of radiotherapy toxicities [13].
Table 2
Baseline characteristics of the REQUITE prostate cancer patients.
Characteristics Radical radiotherapy (N = 1277) Post-prostatectomy patients (N = 483)#
Age at enrolment (median, range) 71 years (42–88) 66 years (46–85)
BMI (mean, standard deviation) 27.7 kg/m2 (±4.5) 27.3 kg/m2 (±3.6)
Smoking status at diagnosis
Current 165 (13%) 84 (17%)
Former 600 (47%) 221 (46%)
Never 508 (40%) 175 (36%)
Selected comorbidities + pre-radiotherapy surgery
Diabetes, antidiabetics 185 (14%) 51 (11%)
Hypertension, hypertensive medication 750 (59%) 237 (49%)
Use of statins, cholesterol lowering drugs 486 (38%) 163 (34%)
History of heart disease 289 (23%) 83 (17%)
Previous abdominal surgery 675 (53%) 175 (36%)
TURP 104 (8%) 10 (2%)
Family history of prostate cancer (1st degree) 220 (17%) 100 (21%)
Tumour size (pre-radiotherapy)*
T1 377 (30%) –
T2 554 (43%) 202 (42%)
T3, T4 220 (16%) 247 (51%)
Nodal status (pre-radiotherapy)*
Negative 1093 (86%) 215 (45%)
Positive 59 (5%) 75 (16%)
Gleason’s score
Gleason < 7 244 (19%) 70 (14%)
Gleason 7 709 (56%) 296 (61%)
Gleason 8–10 320 (25%) 119 (24%)
Pre-diagnostic biopsy PSA (median, range) 9.6 ng/ml (0.35–300) 8.0 ng/ml (0.1–270)
10 ng/ml 681 (53%) 283 (59%)
10–20 ng/ml 337 (26%) 94 (19%)
>20 ng/ml 246 (19%) 53 (11%)
Risk class (National Comprehensive Cancer Network version1.2018)
Low (T1-T2a + Gleason  6 + PSA < 10 ng/ml) 110 (9%) (<1%)
Intermediate (favourable plus unfavourable) (T2b-T2c OR Gleason = 7 OR PSA 10–20) 618 (48%) 180 (37%)
High plus very high (T3-T4 OR Gleason 8–10 OR PSA > 20 ng/ml) 543 (44%) 287 (59%)
Hormonal treatment
None 291 (23%) 248 (51%)
Yes 986 (77%) 235 (49%)
Radiotherapy
EBRT
3D conformal radiotherapy 187 (16%) 101 (21%)
IMRT 145 (12%) 87 (18%)
VMAT 866 (72%) 295 (61%)
Pelvic radiotherapy 363 (28%) 161 (33%)
Total EBRT dose (Gy), without brachytherapy 54.4–81.0 Gy 51.2–77.0 Gy
EBRT regimens without brachytherapy (N = 1578, 90%)
1.6 Gy fraction dose; 59.2 Gy total dose 2 (<1%) –
1.8–2.0 Gy fraction dose; 66–72 Gy total dose 10 (<1%) 317 (66%)
1.8–2.0 Gy fraction dose; 74–81 Gy total dose 745 (68%) 116 (24%)
2.1–2.5 Gy fraction dose; 63–77 Gy total dose 106 (10%) 20 (4%)
>2.5–3.4 Gy fraction dose; 51.2–69.25 Gy total dose 231 (21%) 30 (6%)
EBRT regimens with brachytherapy (N = 103, 6%)
1.8–2.0 Gy fraction dose; 45–50.4 Gy§ 24 (23%) –
2.45–2.54 Gy fraction dose; 36.8–38.1 Gy 79 (77%) –
Brachytherapy 182 (14%) –
Brachytherapy alone 79 (43%) –
HDR 8 (10%) –
LDR 71 (90%) –
HDR dose (Iridium; median, range) 19 Gy (19–25) –
LDR dose (mostly iodine; median, range) 145 Gy (124–160) –
Brachytherapy + EBRT 103 (57%) –
HDR 84 (82%) –
LDR 19 (18%) –
HDR dose (Iridium, Cobalt-60; median, range) 15 Gy (13–21) –
LDR dose (mostly palladium; median, range) 100 Gy (85–108) –
BMI: Body mass index. EBRT: External beam radiation therapy. HDR: High dose rate. IMRT: Intensity-modulated radiation therapy. LDR: Low dose rate. PSA: Prostate specific
antigen. TURP: transurethral resection of the prostate. VMAT: Volumetric Arc Therapy.
#salvage (prostatectomy 12 months prior to RT) 56% and adjuvant (prostatectomy <12 months prior to RT) 44%. *Clinical T/N stages for radical radiotherapy patients and
pathological T/N stages for post-prostatectomy patients. §Including 1 patient with incomplete dosage. Data might not add up to 100% due to missing data.
64 REQUITE cohort characteristicsWe successfully showed that it is possible to collect standard-
ised clinical data prospectively from multiple hospitals across
countries, given adequate funding to perform the labour intensive
work. The actual accrual of 84% of target (4438 versus 5300) was
reduced due to some centres being slow to open and the con-
straints due to funding limited the possibility of extending the
recruitment period. There was a high return rate for question-
naires, e.g. 76% for 24 months PRO data and 81% healthcare profes-
sional reported toxicity in prostate cancer patients. In comparison
single centre studies in prostate cancer patients carried out up to
two years following radiotherapy reported overall questionnairecompletion rates of 50% [30], 85% in ProtecT [31], and 69% in CHHiP
[32]. The REQUITE study also aimed at a low level of missing data,
e.g. only 2% of the 1665 prostate cancer patients with EORTC C30
forms had 10% missing quality-of-life items at baseline. In a
review of randomised control trials on the extent of missing
quality-of-life data, 36% of the studies had >10% missing items
and for 21% the level of missing data was unclear [33].
The REQUITE baseline toxicity rates and quality-of-life scores
were comparable with other studies. For example, 27% of the pros-
tate cancer patients recruited reported grade 2 erectile dysfunc-
tion at baseline compared with 32% in the radiotherapy group of
Table 3
Baseline characteristics of the REQUITE lung cancer patients.
Characteristics Lung cancer patients (N = 530)
Sex Female 158 (30%)
Male 370 (70%)
Age at enrolment Median (range), years 69 years (39–91)
BMI Mean (standard deviation), kg/m2 F: 25.8 (±6.2)
M: 26.6 (±4.8)
Smoking status at diagnosis Current F: 65 (41%) M: 148 (40%)
Former F: 78 (49%) M: 212 (57%)
Never F: 15 (9%) M: 8 (2%)
Selected comorbidities COPD F: 65 (41%) M: 150 (41%)
Tuberculosis of the lung F: 3 (2%) M: 10 (3%)
Diabetes, antidiabetics F: 19 (12%) M: 69 (19%)
Hypertension, hypertensive medication F: 78 (49%) M: 222 (60%)
Heart disease F: 32 (20%) M: 129 (35%)
Family history of lung cancer First degree relatives 94 (18%)
Tumour histology Squamous 176 (33%)
Adenocarcinoma 194 (37%)
Small cell 20 (4%)
Other, undifferentiated 51 (10%)
Radiological diagnosis, unknown 89 (17%)
Clinical tumour size stage (pre-radiotherapy) 0 11 (2%)
1a, 1b 180 (34%)
2a, 2b 139 (26%)
3 or 4 193 (36%)
Clinical nodal stage (pre-radiotherapy) Negative 235 (44%)
Positive 289 (55%)
Tumour stage at diagnosis I-II 232 (44%)
IIIa, IIIb 287 (54%)
Additional cancer treatment Chemotherapy 271 (51%)
– Sequential chemotherapy 62 (23%)
– Concurrent chemotherapy 203 (75%)
– Consolidation chemotherapy 6 (2%)
Surgery 48 (9%)
Radiotherapy technique 3D conformal radiotherapy 161 (30%)
ARC therapy (VMAT, RapidARC) 70 (13%)
IMRT 140 (26%)
Tomotherapy 12 (2%)
Stereotactic body radiotherapy 147 (28%)
Radiotherapy regimens
Conventional fractionation/moderate hypofractionation 383 (72%)
1.5 Gy fraction dose, 30–42 fractions 48 (13%)
1.8–1.99 Gy fraction dose, 25–39 fractions 31 (8%)
2.0 Gy fraction dose, 21–40 fractions 179 (47%)
>2.0–3.0 Gy fraction dose, 20–33 fractions#1 109 (28%)
4.0–5.0 Gy fraction dose, 12–24 fractions#2 16 (4%)
SABR 147 (28%)
3 fractions à 18–20 Gy, total of 45–60 Gy 30 (20%)
4 fractions à 8.75–15 Gy, total of 35–60 Gy 64 (44%)
5 fractions à 10–15.27 Gy, total of 50–76.39 Gy 30 (20%)
8 fractions à 7.5–9.18 Gy, total of 60–73.44 Gy 23 (16%)
BMI: Body mass index. COPD: Chronic obstructive pulmonary disease. F: Female. IMRT: Intensity-modulated radiation therapy. M: Male. SABR: Stereotactic ablative
radiotherapy. VMAT: Volumetric Arc Therapy.
#1Including 5 patients with incomplete dosage. #2Including 1 patient with incomplete dosage.
Numbers may not add up to 100% due to missing data.
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of physician reported grade 2 dyspnoea at baseline in REQUITE
was 23% compared with 15% reported elsewhere [35]. A systematic
review of toxicity reporting in clinical trials identified that only
43% reported baseline data [36], highlighting the lack of reporting
standards for adverse events and the need to improve the collec-
tion of baseline data. A study with 367 cancer patients [37]
reported an EORTC C30 general health status/quality-of-life score
of 67 at start of radiotherapy which is comparable with the
REQUITE scores ranging from 61 to 74 at baseline.
We found that healthcare professional grading of adverse
effects was lower than patient reported scores across three cancer
types (Supplementary Figs. 2a–2d). These findings in a multi-
national setting confirm a previous report [36]. Although the col-
lection of PRO data has become established in clinical trials, chal-
lenges remain to increase understanding of clinical relevance,
and to increase use in routine clinical practice [38]. Definition of
treatment-induced clinically meaningful changes requires stan-
dardisation and is currently subjective [39]. The REQUITE resource
will be useful for future studies developing standards that are
applicable across countries.Randomised controlled trials comparing the efficacy of different
treatments provide a route for collecting multi-centre data, but are
limited by restricted inclusion and exclusion criteria. Our study
cohort reflects ‘‘real world” clinical radiotherapy practice across
countries and will form the basis for further projects to improve
prediction before treatment of those with a higher risk of long-
term adverse effects after radiotherapy. The database can also be
used to study various clinical questions regarding the determi-
nants of long-term adverse effects and the longitudinal effect on
quality-of-life. REQUITE will also enable a better understanding
of the scale of radiotherapy toxicity in a multi-national setting
and can be used to compare similarities and differences between
countries. Country-specific analyses are possible. For example,
fewer US lung cancer patients smoked at time of diagnosis com-
pared to the other countries; male patients from one Spanish
recruitment centre came from rural areas with lower education
levels compared to other recruitment centres; and breast cancer
patients in Germany were more reluctant to answer questions on
sexual activity than in other countries (Supplementary Fig. S3).
The strengths of the REQUITE study are the scale of data col-
lected, use of standardised CRFs, the centralised database and bio-
66 REQUITE cohort characteristicsbank, the quality control methods used to maximise data quality,
and the availability of genotyping data. The majority of cancer
patients consented to share their data and samples with other
researchers outside the REQUITE project. A data and sample access
committee has been established to maximise dissemination of the
resource and a cost-recovery model implemented to ensure
sustainability contact. External researchers can contact
requite@manchester.ac.uk for further information on how to apply
for access to the data (fees apply). The www.requite.eu website
provides an overview of the project and a summary of the patient
characteristics. Limitations of the study include poor recruitment
of lung cancer patients, follow-up currently limited to 2 years
(with extension planned) and the small number of cancer types
studied.
As several toxicities such as breast fibrosis may emerge many
years after completion of radiotherapy, follow-up beyond two
years is desirable. A longer follow-up would also allow assessment
of fluctuations in symptoms over time. Funding for an extension of
the follow-up to five years in some centres was secured through an
ERA PERMED grant.
In summary, we successfully established an international
cohort of more than 4400 cancer patients with radiotherapy and
longitudinal data for future epidemiological studies. The compre-
hensive centralised database and linked biobank is a valuable
resource for the radiotherapy community for validating predictive
models and biomarkers.
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